Merck Serono Rebif meets primary endpoint in Phase III Reflex 1 study
Reflex study was conducted with the serum-free formulation of Rebif 3, which was first introduced in 2007 and is now available in all EU countries, Australia, Canada and
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.